

**TOXICOLOGICAL PROFILE FOR
XYLENE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

August 1995

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

A Toxicological Profile for Xylene was released on October 1993. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on February 28, 1994 (59 FR 9486). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801).

Foreword

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, appearing to read "David Satcher", with a long horizontal line extending to the right.

David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Mike Fay, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Carol Eisenmann, Ph.D.
Sciences International, Inc., Alexandria, VA

Sanjivani Diwan, Ph.D.
Clement International Corporation, Fairfax, VA

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

- 1 . Green Border Review. Green Border review assures the consistency with ATSDR policy.
- 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying endpoints.
- 3 . Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
- 4 . Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

PEER REVIEW

A peer review panel was assembled for xylene. The panel consisted of the following members:

- 1 . Dr. Ingeborg Harding-Barlow, Private Consultant, Palo Alto, California
- 2 . Dr. Shane Que Hee, Associate Professor, Department of Environmental Health Sciences, UCLA School of Public Health, Los Angeles, California
- 3 . Dr. Robert Sherwood, Senior Microbiologist, IIT Research Institute, Chicago, Illinois
- 4 . Dr. Norman Trieff, Professor, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
- 5 . Dr. Charles Ward, Private Consultant, Pittsburgh, Philadelphia

These experts collectively have knowledge of xylene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
CONTRIBUTORS	vii
PEER REVIEW	ix
LIST OF FIGURES	xv
LIST OF TABLES	xvii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS XYLENE?	1
1.2 WHAT HAPPENS TO XYLENE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO XYLENE?	3
1.4 HOW CAN XYLENE ENTER AND LEAVE MY BODY?	5
1.5 HOW CAN XYLENE AFFECT MY HEALTH?	6
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO XYLENE?	7
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	7
1.8 WHERE CAN I GET MORE INFORMATION?	9
2. HEALTH EFFECTS	11
2.1 INTRODUCTION	11
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	11
2.2.1 Inhalation Exposure	13
2.2.1.1 Death	13
2.2.1.2 Systemic Effects	14
2.2.1.3 Immunological and Lymphoreticular Effects	50
2.2.1.4 Neurological Effects	50
2.2.1.5 Reproductive Effects	55
2.2.1.6 Developmental Effects	55
2.2.1.7 Genotoxic Effects	57
2.2.1.8 Cancer	58
2.2.2 Oral Exposure	58
2.2.2.1 Death	58
2.2.2.2 Systemic Effects	59
2.2.2.3 Immunological and Lymphoreticular Effects	82
2.2.2.4 Neurological Effects	82
2.2.2.5 Reproductive Effects	83
2.2.2.6 Developmental Effects	84
2.2.2.7 Genotoxic Effects	84
2.2.2.8 Cancer	85
2.2.3 Dermal Exposure	85
2.2.3.1 Death	85
2.2.3.2 Systemic Effects	86

2.2.3.3	Immunological and Lymphoreticular Effects	90
2.2.3.4	Neurological Effects	91
2.2.3.5	Reproductive Effects	91
2.2.3.6	Developmental Effects	91
2.2.3.7	Genotoxic Effects	92
2.2.3.8	Cancer	92
2.3	TOXICOKINETICS	93
2.3.1	Absorption	93
2.3.1.1	Inhalation Exposure	93
2.3.1.2	Oral Exposure	94
2.3.1.3	Dermal Exposure	95
2.3.2	Distribution	96
2.3.2.1	Inhalation Exposure	96
2.3.2.2	Oral Exposure	97
2.3.2.3	Dermal Exposure	97
2.3.3	Metabolism	97
2.3.4	Excretion	101
2.3.4.1	Inhalation Exposure	101
2.3.4.2	Oral Exposure	103
2.3.4.3	Dermal Exposure	104
2.3.4.4	Other Routes of Exposure	104
2.3.5	Mechanisms of Action	105
2.4	RELEVANCE TO PUBLIC HEALTH	106
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	122
2.5.1	Biomarkers Used to Identify or Quantify Exposure to Xylene	123
2.5.2	Biomarkers Used to Characterize Effects Caused by Xylene	124
2.6	INTERACTIONS WITH OTHER SUBSTANCES	124
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	127
2.8	METHODS FOR REDUCING TOXIC EFFECTS	129
2.8.1	Reducing Peak Absorption Following Exposure	129
2.8.2	Reducing Body Burden	130
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	130
2.9	ADEQUACY OF THE DATABASE	131
2.9.1	Existing Information on Health Effects of Xylene	132
2.9.2	Identification of Data Needs	134
2.9.3	On-going Studies	141
3.	CHEMICAL AND PHYSICAL INFORMATION	143
3.1	CHEMICAL IDENTITY	143
3.2	PHYSICAL AND CHEMICAL PROPERTIES	143
4.	PRODUCTION, IMPORT, USE, AND DISPOSAL	147
4.1	PRODUCTION	147
4.2	IMPORT/EXPORT	154
4.3	USE	156
4.4	DISPOSAL	156
5.	POTENTIAL FOR HUMAN EXPOSURE	157
5.1	OVERVIEW	157

5.2	RELEASES TO THE ENVIRONMENT	159
5.2.1	Air	159
5.2.2	Water	168
5.2.3	Soil	169
5.3	ENVIRONMENTAL FATE	169
5.3.1	Transport and Partitioning	169
5.3.2	Transformation and Degradation	173
5.3.2.1	Air	173
5.3.2.2	Water	174
5.3.2.3	Sediment and Soil	176
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	177
5.4.1	Air	177
5.4.2	Water	179
5.4.3	Sediment and Soil	180
5.4.4	Other Environmental Media	180
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	181
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	186
5.7	ADEQUACY OF THE DATABASE	186
5.7.1	Identification of Data Needs	187
5.7.2	On-going Studies	190
6.	ANALYTICAL METHODS	193
6.1	BIOLOGICAL MATERIALS	193
6.2	ENVIRONMENTAL SAMPLES	201
6.3	ADEQUACY OF THE DATABASE	208
6.3.1	Identification of Data Needs	208
6.3.2	On-going Studies	210
7.	REGULATIONS AND ADVISORIES	211
8.	REFERENCES	217
9.	GLOSSARY	267
APPENDICES		
A.	USER'S GUIDE	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	B-1

LIST OF FIGURES

2-1.	Levels of Significant Exposure to Mixed Xylene - Inhalation	34
2-2.	Levels of Significant Exposure to <i>m</i> -Xylene - Inhalation	37
2-3.	Levels of Significant Exposure to <i>o</i> -Xylene - Inhalation	39
2-4.	Levels of Significant Exposure to <i>p</i> -Xylene - Inhalation	41
2-5.	Levels of Significant Exposure to Mixed Xylene - Oral	71
2-6.	Levels of Significant Exposure to <i>m</i> -Xylene - Oral	74
2-7.	Levels of Significant Exposure to <i>o</i> -Xylene - Oral	75
2-8.	Levels of Significant Exposure to <i>p</i> -Xylene - Oral	76
2-9.	Metabolic Scheme for Xylenes - Humans	99
2-10.	Metabolic Scheme for Xylenes - Animals	100
2-11.	Existing Information on Health Effects of Total Xylenes	133
5-1.	Frequency of NPL Sites with Xylene Contamination	158

LIST OF TABLES

2-1.	Levels of Significant Exposure to Mixed Xylene - Inhalation	15
2-2.	Levels of Significant Exposure to <i>m</i> -Xylene - Inhalation	22
2-3.	Levels of Significant Exposure to <i>o</i> -Xylene - Inhalation	26
2-4.	Levels of Significant Exposure to <i>p</i> -Xylene - Inhalation	30
2-5.	Levels of Significant Exposure to Mixed Xylene - Oral	60
2-6.	Levels of Significant Exposure to <i>m</i> -Xylene - Oral	66
2-7.	Levels of Significant Exposure to <i>o</i> -Xylene - Oral	68
2-8.	Levels of Significant Exposure to <i>p</i> -Xylene - Oral	69
2-9.	Levels of Significant Exposure to Mixed Xylene - Dermal	87
2-10.	Levels of Significant Exposure to <i>m</i> -Xylene - Dermal	88
2-11.	Genotoxicity of Xylene <i>In Vitro</i>	117
2-12.	Genotoxicity of Xylene <i>In Vivo</i>	120
3-1.	Chemical Identity of <i>m</i> -Xylene, <i>o</i> -Xylene, <i>p</i> -Xylene, and Mixed Xylene	144
3-2.	Physical and Chemical Properties of <i>m</i> -Xylene, <i>o</i> -Xylene, <i>p</i> -Xylene, and Mixed Xylene . .	145
4-1.	Producers of Xylene and Estimated Annual Capacities	148
4-2.	Facilities That Manufacture or Process Mixed Xylene	149
4-3.	Facilities That Manufacture or Process <i>m</i> -Xylene	151
4-4.	Facilities That Manufacture or Process <i>o</i> -Xylene	152
4-5.	Facilities That Manufacture or Process <i>p</i> -Xylene	153
4-6.	U.S. Import and Export Data on Xylenes	155
5-1.	Releases to the Environment from Facilities That Manufacture or Process Mixed Xylene	160
5-2.	Releases to the Environment from Facilities That Manufacture or Process <i>m</i> -Xylene	163
5-3.	Releases to the Environment from Facilities That Manufacture or Process <i>o</i> -Xylene	165
5-4.	Releases to the Environment from Facilities That Manufacture or Process <i>p</i> -Xylene	167
5-5.	Characteristics of Different Environmental Compartments and Xylene Concentrations on Emissions of 100 mol	170
5-6.	Percentage Breakdown of NIOSH Occupational Exposure Estimates from the NOHS and NOES Databases	185
6-1.	Analytical Methods for Determining Xylene in Biological Materials	194
6-2.	Analytical Methods for Determining Xylene in Environmental Samples	202
7-1.	Regulations and Guidelines Applicable to Xylene	212

